Lamivudine, nevirapine, stavudine
Sold as Tridex, Virtrium, Stalanev, Triomune, Sonke-laminevstav
Combination product
This product contains more than one active ingredient, so it has no single molecular structure.
Background
Registration
- Applicants
- 5
- Registrations
- 8
- Schedule source
- Consolidated Schedules 06 July 2026
Applicants and registrations
| Applicant | Brands | Dosages | Registrations | Schedule | Leaflets |
|---|---|---|---|---|---|
| Dezzo Trading 392 (Pty) LtdCancelled | Tridex | Not stated | 410182 | S4 | None |
| Pharmacare limited û woodmead | Virtrium | 30/150/200, 40/150/200 | 420563, 420564 | S4 | None |
| Aurogen South Africa (Pty) LtdCancelled | Stalanev | Not stated | 430848 | S4 | None |
| Cipla Medpro (Pty) LtdCancelled | Triomune | 30, 40 | A380409, A400460 | S4 | None |
| Ranbaxy Pharmaceutical (Pty) LtdCancelled | Sonke-laminevstav | 30, 40 | A400659, A400660 | S4 | None |
Variants
| Product | Strength and form | Registration | Status | Schedule | Leaflets |
|---|---|---|---|---|---|
| Tridex EACH TABLET CONTAINS LAMIVUDINE 150,0 mg NEVIRAPINE 200,0 mg STAVUDINE 40,0 mg | Not listed | 41018241/20.2.8/0182 | Cancelled | S4 | None |
| Virtrium 30/150/200 EACH TABLET CONTAINS LAMIVUDINE 150,0 mg NEVIRAPINE 200,0 mg STAVUDINE 30,0 mg | 30/150/200 | 42056342/20.2.8/0563 | Registered | S4 | None |
| Virtrium 40/150/200 EACH TABLET CONTAINS LAMIVUDINE 150,0 mg NEVIRAPINE 200,0 mg STAVUDINE 40,0 mg | 40/150/200 | 42056442/20.2.8/0564 | Registered | S4 | None |
| Stalanev EACH TABLET CONTAINS LAMIVUDINE 150,0 mg NEVIRAPINE 200,0 mg STAVUDINE 30,0 mg | Not listed | 43084843/20.2.8/0848 | Cancelled | S4 | None |
| Triomune 40 EACH TABLET CONTAINS LAMIVUDINE 150,0 mg NEVIRAPINE 200,0 mg STAVUDINE 40,0 mg | 40 | A380409A38/20.2.8/0409 | Cancelled | S4 | None |
| Triomune 30 EACH TABLET CONTAINS LAMIVUDINE 150,0 mg NEVIRAPINE 200,0 mg STAVUDINE 30,0 mg | 30 | A400460A40/20.2.8/0460 | Cancelled | S4 | None |
| Sonke-laminevstav 30 EACH TABLET CONTAINS LAMIVUDINE 150,0 mg NEVIRAPINE 200,0 mg STAVUDINE 30,0 mg | 30 | A400659A40/20.2.8/0659 | Cancelled | S4 | None |
| Sonke-laminevstav 40 EACH TABLET CONTAINS LAMIVUDINE 150,0 mg NEVIRAPINE 200,0 mg STAVUDINE 40,0 mg | 40 | A400660A40/20.2.8/0660 | Cancelled | S4 | None |
Regulatory status
Where S4 sits on the scale
Prescription-only medicine.
Schedule 4 covers most ordinary prescription medicines. You need a prescription from an authorised prescriber, such as a doctor or dentist, and a pharmacist dispenses it. Its price, name, pack size and strength can still be told to the public, as long as nothing links it to what it treats.
Schedule S4, matched to the Consolidated Schedules by ingredient, confidence medium.
Who may supply: A pharmacist dispensing against a written or verbal prescription from an authorised prescriber; a veterinarian, who may also prescribe, compound or dispense it directly; a medical practitioner or dentist, who may prescribe it and may compound or dispense it directly only if licensed under section 22C(1)(a); manufacturers and wholesalers may supply people who may lawfully possess it; and, for animal treatment, a person practising a para-veterinary profession, on a veterinarian's written or verbal instruction.
Consolidated Schedules listings for Lamivudine, nevirapine, stavudine
S4: Lamivudine
Consolidated Schedules 06 July 2026, line 6850
S4: Nevirapine
Consolidated Schedules 06 July 2026, line 7245
S4: Stavudine
Consolidated Schedules 06 July 2026, line 7974
Pharmacological class: Antiviral agents. (class 20.2.8)
This is an informational summary of the Medicines and Related Substances Act 101 of 1965 and its 2017 General Regulations. It is not medical advice and not legal advice. Always check the medicine's label, which carries the schedule number inside a square border, or ask a pharmacist if you are unsure.
SAHPRA documents
SAHPRA has not published a professional information or patient information leaflet for this product.